BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Takeda Leaps Into NASH With $470M-Plus Deal With HemoShear Therapeutics

  Takeda is jumping into the $40B market for NASH and other diseases of the liver with a $470M+ investment into HemoShear Therapeutics.

  October 17, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  450 Jobs Eliminated as Novartis Shuts Down Colorado Facility

  Novartis is closing its generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.

  October 17, 2017

   · 

  3 min read

   · 

  Mark Terry
• Drug Development

  OncBioMune Preparing to Initiate Trials of Novel Therapeutic Ovarian Cancer Vaccine

  OncBioMune has begun the process to initiate clinical studies of OvcaVax for ovarian cancer.

  October 17, 2017

   · 

  4 min read
• Business

  Genmab Announces Net Sales of DARZALEX (Daratumumab) for Third Quarter of 2017

  Net sales of DARZALEX in the third quarter of 2017 totaled USD 317 million.

  October 17, 2017

   · 

  6 min read
• 

  Policy

  J&J Terminates Two Drugs From Pipeline

  Buried in its third-quarter financial announcement, J&J indicated it was dropping two of its pipeline drugs with little or no explanation.

  October 17, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  Amneal and Impax to Marry, Creating the 5th Largest Generics Biz in the U.S.

  Amneal and Impax are combining into a new entity that is expected to have the fifth largest generics business in the United States.

  October 17, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Pharm Country

  3 Biotechs That Got Huge Boosts From Spark’s FDA Panel Vote

  On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark’s Luxturna in a vote of 16 to 0.

  October 17, 2017

   · 

  2 min read

   · 

  Mark Terry
• Job Trends

  Drug R&D Boom Lead Massachusetts Biotech Jobs to Hit an All-Time High

  And industry trade group MassBio has the jobs numbers and pipeline data to prove it.

  October 17, 2017

   · 

  1 min read
• 

  Business

  Cambridge’s Cydan Scores $34M, Names a New CMO

  Cydan snagged $34M to fund its rare disease pipeline and also tapped two new members of its executive leadership team.

  October 17, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Ignyta Stock Booms on Promising Mid-Stage Lung Cancer Data

  The good news led Ignyta’s stock to jump about five percent before settling down.

  October 17, 2017

   · 

  3 min read

   · 

  Mark Terry